RecruitingNot ApplicableNCT04699279

Protective Effect of Statin Against Negative Cardiovascular Remodeling and Organ Dysfunction After Acute Aortic Syndrome Surgery (PANDA III)


Sponsor

Nanjing Medical University

Enrollment

300 participants

Start Date

Jan 1, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

Acute Aortic Syndrome (AAS)/Aortic Aneurysm is a common feature of aortic wall events, including aortic dissection, intramural hematoma, aortic ulceration and aortic trauma, and occurs in up to 35 cases per 100,000 cases per year between the ages of 65 and 75 years. Increased levels of the inflammatory biomarker high-sensitivity C-reactive protein predict cardiovascular events. Since statins lower levels of high-sensitivity C-reactive protein as well as cholesterol, the authors hypothesized that people with acute aortic syndrome but without hyperlipidemia might benefit from statin treatment.


Eligibility

Min Age: 18 YearsMax Age: 85 Years

Inclusion Criteria4

  • (1) Patients with aortic dissection/ulceration/intermural hematoma/aortic aneurysm who underwent aortic arch replacement or endoluminal isolation or hybrid therapy;
  • (2) Paitents without clinically significant hyperlipidemia but with cardiovascular disease risk factors (such as male ≥45 years old, female ≥55 years old, hypertension, diabetes, chronic kidney disease, obesity, low HDL cholesterol, smoking, alcohol consumption, family history of early onset ischemic cardiovascular disease) and no previous use of statins;
  • (3) Patients are between 18 and 85 years old, male or female;
  • (4) Agree to participate in the study and sign the informed consent.

Exclusion Criteria6

  • (1) Patients with allergy to statins;
  • (2) patients with active liver disease;
  • (3) patients with myopathy;
  • (4) Lactating women and pregnant women;
  • (5) Patients with mental diseases, drug and alcohol dependence;
  • (6) Refuse to participate in the study or sign the informed consent.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRosuvastatin 10mg

Rosuvastatin 10mg is taken by oral or nasal feeding every day at ang time.


Locations(5)

The First Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China

The first affiliated hospital of nanjing medical university

Nanjing, Jiangsu, China

Affiliated Hospital of Qingdao University

Qingdao, Shandong, China

West China Hospital of Sichuan University

Chengdu, Sichuan, China

Beijing Anzhen Hospital

Beijing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04699279


Related Trials